Search

Search Constraints

You searched for: Author/Creator Obr, Ales

Search Results

1. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. (30th August 2020)

2. Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma. Issue 1 (30th October 2017)

3. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world. (11th May 2022)

4. Rituximab maintenance significantly prolongs progression‐free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Issue 2 (13th December 2018)